COMMUNIQUÉS West-GlobeNewswire

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
12/12/2024
Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF [...]
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
12/12/2024
Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 11 décembre 2024
12/12/2024
Daix (France), New York City (New York, Etats-Unis), le 11 décembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
VelaLabs Announces Strategic Partnership with EarlyHealth Group to Support Biological Drugs Development
12/12/2024
VIENNA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- VelaLabs GmbH, a leading provider of analytical and quality services for biopharmaceutical development, has signed a Memorandum of Understanding (MoU) with EarlyHealth Group to [...]
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
12/12/2024
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: [...]
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction
12/12/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion’s Board of Directors for delay in [...]
FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research
12/12/2024
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024 , held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements [...]
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
12/12/2024
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for [...]
EssilorLuxottica: EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi)
12/12/2024
EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi) Paris, France (12 December 2024) – EssilorLuxottica announced today that its near-term greenhouse [...]
EssilorLuxottica: Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi)
12/12/2024
Les objectifs à court terme de réduction des émissions de gaz à effet de serre d'EssilorLuxottica ont été validés par l’initiative Science Based Target (SBTi) Paris, France (12 décembre 2024) – EssilorLuxottica a [...]
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12/12/2024
Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings [...]
ACARIZAX® approved in Europe for treatment of young children
12/12/2024
ALK ( ALKB:DC / OMX: ALK B ) today announced that its European regulatory filing for ACARIZAX ® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health [...]
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors
12/12/2024
Dr. Doberstein brings extensive biotech leadership experience as the company advances its AI-powered pipeline into Phase 2 for immune-mediated inflammatory disorders GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- [...]
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
12/12/2024
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
XORTX Announces Presentation at the Rare and Genetic Disease Summit
12/12/2024
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12/12/2024
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032 [...]
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12/12/2024
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE [...]
HWH International Inc. announces plans to expand its Robotics division into the U.S. by establishing a Dallas, Texas based showroom and starting its marketing efforts in the 1st quarter of 2025.
12/12/2024
BETHESDA, MD, Dec. 12, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) is proud to announce its plans to begin its marketing efforts in the U.S. in the first quarter of 2025. The Company’s wholly [...]
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
12/12/2024
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose ( [...]

Pages